

TRUE-PTX Eluvia Subgroup Analysis¹



Eluvia DES vs. non-DE Devices (BMS, PTA)

Objective	Compare outcomes in patients with peripheral artery disease (PAD) treated with Eluvia DES vs. those treated with non-DE devices.		
Presenter	Brian DeRubertis, MD Weill Cornell Medicine, New York, NY, USA		
Study Design	Comparative propensity score matched analysis ² of de-identified electronic health record (EHR) data		
Data Source	Truveta aggregates normalized EHR data from more than 120 million de-identified patient records across more than 30 U.S. health systems		
Patients	 N = 6,037 (N = 881 Eluvia; N = 5,156 non-DE) Patients with PAD undergoing Eluvia or non-drug eluting endovascular balloon or stent therapy 		

RESULTS

BEFORE MATCHING

12-month amputations and readmissions before matching for clinical and demographic characteristics

	Eluvia	non-DE	P-value
Any Limb Amputation	7.5%	8.9%	0.265
Same Limb Amputation	1.9%	2.3%	0.391
Any Readmission	51.9%	57.8%	0.001

AFTER MATCHING²

Patients treated with <u>non-DE devices</u> were more likely to have any above-ankle amputation and any readmission compared with Eluvia DES

Treatment with a <u>non-DE</u>

<u>device</u> increased odds for any

above-ankle amputation by

47%

Treatment with a <u>non-DE</u>

<u>device</u> increased odds for any
readmission by

23%





ELUVIA™ DRUG-ELUTING VASCULAR STENT SYSTEM

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

Peripheral Interventions www.bostonscientific.eu © 2025 Boston Scientific Corporation or its affiliates. All rights reserved. PI-2167002-AA **(€**0344